OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
BörsenkürzelOABIW
Name des UnternehmensOmniAb Inc
IPO-datumOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Anzahl der mitarbeiter- -
WertpapierartCompany Warrant
Geschäftsjahresende- -
Addresse5980 Horton Street
StadtEMERYVILLE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94608
Telefon15102507800
Websitehttps://www.omniab.com/
BörsenkürzelOABIW
IPO-datumOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten